Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1995 Jan;40(1):1–9. doi: 10.1007/BF01517229

CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion

Roya Dadmarz 1,✉, Magdalene K Sgagias 1, Steven A Rosenberg 1, Douglas J Schwartzentruber 1
PMCID: PMC11037666  PMID: 7828162

Abstract

Tumor-infiltrating lymphocytes (TIL) were derived from primary breast tumors, metastatic lymph nodes and malignant pleural effusions from 34 patients with breast cancer. TIL were cultured for approximately 30 days and studied for phenotype, cytotoxicity, and the ability to secrete cytokines in response to autologous tumor stimulation. Tumor specimens were obtained from two different sites in 7 patients, resulting in 41 samples from which 38 TIL cultures were established. In addition to screening 38 bulk TIL cultures, TIL from 21 patients were separated into CD4+ and CD8+ subsets and extensively studied. Three CD4+ TIL were found specifically to secrete granulocyte macrophage-colony-stimulating factor and tumor necrosis factor α when stimulated by autologous tumor and not by a large panel of stimulators (24–34) consisting of autologous normal cells, allogeneic breast or melanoma tumors and EBV-B cells. This cytokine release was found to be MHC-class-II-restricted, as it was inhibited by the anti-HLA-DR antibody L243. These 3 patients' EBV-B cells, when pulsed with tumor lysates, were unable to act as antigen-presenting cells and induce cytokine secretion by their respective CD4+ TIL. These findings demonstrate that MHC-class-II-restricted CD4+ T cells recognising tumor-associated antigens can be detected in some breast cancer patients.

Key words: Breast cancer, CD4+ T cells, MHC-class-II-restriction, Cytokine secretion

References

  • 1.Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K. Patterns of human infiltrating lymphocytes in 120 human cancers. Arch Surg. 1990;125:2001. doi: 10.1001/archsurg.1990.01410140078012. [DOI] [PubMed] [Google Scholar]
  • 2.Bilik R, Mor C, Hazaz B, Moroz C. Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother. 1989;28:143. doi: 10.1007/BF00199115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Brasseur F, Marchand M, Vanwijck R, Herin M, Lethe B, Chomez P, Boon T. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer. 1992;52:839. doi: 10.1002/ijc.2910520528. [DOI] [PubMed] [Google Scholar]
  • 4.Crannage KE, Rogers K, Jacob G, Stoddard CJ, Thomas WEG, Potter CW, Rees RC. Factors influencing the establishment of tumor-infiltrating lymphocyte cultures from human breast carcinoma and colon carcinoma tissue. Eur J Cancer. 1991;27:149. doi: 10.1016/0277-5379(91)90475-s. [DOI] [PubMed] [Google Scholar]
  • 5.Cresswell P, Avva RR, Davis JE, Lamb CA, Riberdy JM, Roche PP. Intracellular transport and peptide binding properties of HLA class II glycoproteins. Semin Immunol. 1990;2:273. [PubMed] [Google Scholar]
  • 6.Eremin O, Coombs RRA, Ashby J. Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br J Cancer. 1981;44:166. doi: 10.1038/bjc.1981.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Germain RN. The ins and outs of antigen processing and presentation. Nature. 1986;322:687. doi: 10.1038/322687a0. [DOI] [PubMed] [Google Scholar]
  • 8.Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother. 1991;10:153. [PubMed] [Google Scholar]
  • 9.Hom S, Rosenberg SA, Topalian SL. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol Immunother. 1993;36:1. doi: 10.1007/BF01789124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2. 1-transfected melanomas. J Immunol. 1992;148:638. [PubMed] [Google Scholar]
  • 11.Lwin KY, Zuccarini O, Sloane JP, Beverly PCL. An immunohistochemical study of leucocyte localisation in benign and malignant breast tissue. Int J Cancer. 1985;36:433. doi: 10.1002/ijc.2910360404. [DOI] [PubMed] [Google Scholar]
  • 12.Maleckar JR, Friddell CS, Sferruzza A, Thurman GB, Lewko WM, West WH, Oldham RK, Yannelli JR. Activation and expansion of tumor-derived activated cells for therapeutic use. J Natl Cancer Inst. 1989;81:1655. doi: 10.1093/jnci/81.21.1655. [DOI] [PubMed] [Google Scholar]
  • 13.Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatents on proliferative responses of lymphocytes. J Immunol. 1986;136:1899. [PubMed] [Google Scholar]
  • 14.Moraes ME, Fernandez-Vina M, Stastny P. DNA typing for class II HLA antigens with allele-specific or group-specific amplification. IV. Typing for alleles of the HLA-DR2 group. Hum Immunol. 1991;31:139. doi: 10.1016/0198-8859(91)90017-4. [DOI] [PubMed] [Google Scholar]
  • 15.Morecki S, Topalian SL, Myers WW, Okrongly D, Okarma TB, Rosenberg SA. Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated plates. J Biol Response Mod. 1990;9:463. [PubMed] [Google Scholar]
  • 16.Orsini DLM, Res PCM, Van Laar JM, Muller LM, Soprano AEL, Kooy YMC, Tak PP, Koning F. A subset of Vδ1+ T cells proliferates in response to Epstein-Barr virus-transformed B cell lines in vitro. Scand J Immunol. 1993;38:335. doi: 10.1111/j.1365-3083.1993.tb01735.x. [DOI] [PubMed] [Google Scholar]
  • 17.Peoples GE, Goedegebuure PS, Andrews JVR, Schoof DD, Eberlein TJ. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol. 1993;151:5481. [PubMed] [Google Scholar]
  • 18.Rowe DJ, Beverley PCL. Characterisation of breast cancer infiltrates using monoclonal antibodies to human leukocyte antigens. Br J Cancer. 1984;49:149. doi: 10.1038/bjc.1984.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rubbert A, Manger B, Lang N, Kalden JR, Platzer E. Functional characterization of tumor infiltrating lymphocytes, lymph node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer. 1991;49:25. doi: 10.1002/ijc.2910490106. [DOI] [PubMed] [Google Scholar]
  • 20.Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of GM-CSF, TNF-α and IFN-γ by human tumor infiltrating lymphocytes following autologous tumor stimulation. J Immunol. 1991;146:3674. [PubMed] [Google Scholar]
  • 21.Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother. 1992;12:1. doi: 10.1097/00002371-199207000-00001. [DOI] [PubMed] [Google Scholar]
  • 22.Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, Topalian SL. Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony stimulating factor and tumor necrosis factor-α in response to autologous tumor stimulation. Blood. 1993;82:1204. [PubMed] [Google Scholar]
  • 23.Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987;102:127. doi: 10.1016/s0022-1759(87)80018-2. [DOI] [PubMed] [Google Scholar]
  • 24.Topalian SL, Solomon D, Rosenberg SA. Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989;142:3714. [PubMed] [Google Scholar]
  • 25.Topalian SL, Mancini M, Rivoltini L, Ng J, Hartzman RJ, Rosenberg SA. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr Virus transformed B cells. Int J Cancer. 1994;58:69. doi: 10.1002/ijc.2910580113. [DOI] [PubMed] [Google Scholar]
  • 26.Torsteinsdottir S, Masucci MG, Brautbar C, Lenoir G, Klein G, Klein E. Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones. Cell Immunol. 1986;98:453. doi: 10.1016/0008-8749(86)90304-7. [DOI] [PubMed] [Google Scholar]
  • 27.Vose BM, Moore M. Supperssor cell activity of lymphocytes infiltrating human lung and breast tumors. Int J Cancer. 1979;24:579. doi: 10.1002/ijc.2910240510. [DOI] [PubMed] [Google Scholar]
  • 28.Whitford P, Mallon EA, George WD, Campbell AM. Flow cytometric analysis of tumor infiltrating lymphocytes in breast cancer. Br J Cancer. 1990;62:971. doi: 10.1038/bjc.1990.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Yewdell JW, Bennink JR. The binary logic of antigen processing and presentation to T cells. Cell. 1990;62:203. doi: 10.1016/0092-8674(90)90356-j. [DOI] [PubMed] [Google Scholar]
  • 30.Zachary AA, Teresi GA, editors. ASHI laboratory manual. 2nd edn. New York: American Society for Histocompatibility and Immunogenetics; 1990. p. 195. [Google Scholar]
  • 31.Zuk JA, Walker RA. Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J Pathol. 1987;152:275. doi: 10.1002/path.1711520406. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES